Critical appraisal of the guidelines for the management of ankylosing spondylitis: Disease-modifying antirheumatic drugs

Enrique R. Soriano, Daniel O. Clegg, Jeffrey R. Lisse

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Surprisingly, little data are available for the use of disease-modifying antirheumatic drugs in ankylosing spondylitis. Sulfasalazine has been the best studied. Efficacy data for individual agents (including pamidronate) and combinations of agents are detailed in this review. Intriguingly, these agents continue to be used with some frequency, even in the absence of efficacy data. To answer these questions, additional systematic studies of these agents in ankylosing spondylitis are needed and will likely need to be done by interested collaborative groups such as SPARTAN.

Original languageEnglish (US)
Pages (from-to)357-359
Number of pages3
JournalAmerican Journal of the Medical Sciences
Volume343
Issue number5
DOIs
StatePublished - May 1 2012

Keywords

  • Ankylosing spondylitis
  • Disease-modifying
  • Spondyloarthridities
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Critical appraisal of the guidelines for the management of ankylosing spondylitis: Disease-modifying antirheumatic drugs'. Together they form a unique fingerprint.

Cite this